Travere Therapeutics, Inc. (TVTX) Financial Analysis & Valuation | Quarter Chart
Travere Therapeutics, Inc. (TVTX)
TVTXPrice: $58.3
Fair Value: 🔒
🔒score
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radioluc... more
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development,... more
Description
Shares
| Market Cap | $5.42B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Eric Dube |
| IPO Date | 2012-11-08 | CAGR | — |
| Employees | 385 | Website | www.travere.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
TVTX chart loading...
Fundamentals
Technicals
| Enterprise Value | $4.28B | P/E Ratio | -265 |
| Forward P/E | 12.02 | PEG Ratio | — |
| P/S Ratio | 303.64 | P/B Ratio | 1629.96 |
| P/CF Ratio | 4063.65 | P/FCF Ratio | 9346.06 |
| EPS | $-0.22 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 96.03% | Gross Margin | 0.94% |
| Operating Margin | -0.11% | Profit Margin | -0.04% |
| ROE | -0.27% | ROA | -0.04% |
| ROCE | -0.13% | Current Ratio | 3.13 |
| Quick Ratio | 3.08 | Cash Ratio | 0.62 |
| Debt/Equity | 3.32 | Interest Coverage | -5.6 |
| Altman Z Score | 4.66 | Piotroski Score | 4 |